BioTelemetry Inc (NASDAQ:BEAT)’s share price dropped 5.2% during mid-day trading on Monday . The company traded as low as $59.72 and last traded at $60.54. Approximately 459,953 shares traded hands during trading, an increase of 10% from the average daily volume of 419,458 shares. The stock had previously closed at $63.83.

Several equities research analysts have recently weighed in on the company. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a research note on Saturday, November 3rd. Raymond James reduced their price objective on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Wednesday, October 31st. SunTrust Banks raised their price objective on BioTelemetry to $67.00 and gave the stock a “buy” rating in a research note on Friday, August 31st. Finally, Lake Street Capital raised their price objective on BioTelemetry from $50.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 26th. Eight equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $61.17.

The stock has a market capitalization of $2.13 billion, a P/E ratio of 62.41, a price-to-earnings-growth ratio of 3.71 and a beta of 1.58. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.68 and a quick ratio of 2.50.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, October 30th. The medical research company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.21. The business had revenue of $100.00 million during the quarter, compared to analysts’ expectations of $97.89 million. BioTelemetry had a return on equity of 22.56% and a net margin of 4.34%. BioTelemetry’s revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.16 earnings per share. Equities research analysts predict that BioTelemetry Inc will post 1.72 earnings per share for the current fiscal year.

In related news, SVP Daniel Wisniewski sold 31,000 shares of the stock in a transaction on Friday, August 31st. The stock was sold at an average price of $60.45, for a total transaction of $1,873,950.00. Following the completion of the sale, the senior vice president now directly owns 57,291 shares in the company, valued at $3,463,240.95. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kirk E. Gorman sold 625 shares of the stock in a transaction on Monday, September 17th. The stock was sold at an average price of $62.30, for a total value of $38,937.50. Following the sale, the director now owns 173,940 shares of the company’s stock, valued at $10,836,462. The disclosure for this sale can be found here. In the last ninety days, insiders sold 205,852 shares of company stock valued at $12,869,047. 8.30% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in BEAT. Spectrum Management Group Inc. purchased a new stake in shares of BioTelemetry during the third quarter worth $115,000. Thompson Davis & CO. Inc. raised its holdings in shares of BioTelemetry by 112.0% during the second quarter. Thompson Davis & CO. Inc. now owns 2,650 shares of the medical research company’s stock worth $119,000 after acquiring an additional 1,400 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of BioTelemetry during the third quarter worth $145,000. IFP Advisors Inc raised its holdings in shares of BioTelemetry by 163.0% during the third quarter. IFP Advisors Inc now owns 2,927 shares of the medical research company’s stock worth $189,000 after acquiring an additional 1,814 shares in the last quarter. Finally, OppenheimerFunds Inc. purchased a new stake in shares of BioTelemetry during the second quarter worth $205,000. Institutional investors and hedge funds own 92.16% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dailypolitical.com/2018/11/19/biotelemetry-beat-shares-down-5-2.html.

BioTelemetry Company Profile (NASDAQ:BEAT)

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Recommended Story: Stock Symbol

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.